Neurobiology and Therapeutic Targets of Parkinson’s Disease
After Alzheimer’s Disease, the second most prevalent neurodegenerative disease is Parkinson or Parkinson’s Disease (PD). The diagnosis of this disease...
Category: Parkinson disease
Parkinson plus syndrome ch. 3. rd
Progressive Supranuclear Palsy Progressive supranuclear palsy (PSP) is reportedly the second most common cause of idiopathic parkinsonism. Generally, there is...
Parkinson plus syndrome ch. 2. nd
Neuroimaging Neuroimaging findings in patients with MSA correlate partially with the neuronal subsystems involved. All clinical subtypes tend to cause...
Parkinson plus syndrome ch. 1. st
Several primary neurodegenerative disorders share parkinsonian features, such as bradykinesia, rigidity, tremor, and gait disturbances. These disorders have complex clinical...
Visual Test May Flag Risk for Parkinson’s Dementia
VANCOUVER — An online visual test may identify patients with Parkinson’s disease (PD) at highest risk for dementia, results of...
Visual Dysfunction: An Underrecognized Symptom of Parkinson’s?
Visual symptoms are a potentially underrecognized and undertreated cause of reduced quality of life in Parkinson disease patients, a new...
Urine Biomarker Correlates With Parkinson’s Risk Factor Gene
NICE, France — Levels of a group of urinary markers correlate with the LRRK2 G2019S gain-of-kinase function gene mutation, a...
Parkinson’s Subtypes Predict Prognosis
Patients with Parkinson’s disease may be stratified on the basis of specific subtypes that progress differently and that are associated...
Mixed Results With Leukemia Drug in Parkinson’s
A phase 2 placebo-controlled trial of the leukemia drug nilotinib (Tasigna, Novartis) in Parkinson disease suggests the drug is “reasonably safe,”...
